Prostate

• 

  Publication Venue For

  • Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.  75:463-473. 2015
  • Association between systemic inflammatory markers and serum prostate-specific antigen in men without prostatic disease - the 2001-2008 National Health and Nutrition Examination Survey..  74:561-567. 2014
  • Enrichment of putative prostate cancer stem cells after androgen deprivation: Upregulation of pluripotency transactivators concurs with resistance to androgen deprivation in LNCaP cell lines.  73:1378-1390. 2013
  • PC3 is a cell line characteristic of prostatic small cell carcinoma.  71:1668-1679. 2011
  • Effect of intermittent fasting with or without caloric restriction on prostate cancer growth and survival in SCID mice..  70:1037-1043. 2010
  • Selective expression of CD44, a putative prostate cancer stem cell marker, in neuroendocrine tumor cells of human prostate cancer.  69:787-798. 2009
  • Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2 B15 and B17 genes.  68:839-848. 2008
  • Analysis of the gene coding for the BRCA2-interacting protein PALB2 in hereditary prostate cancer..  68:675-678. 2008
  • Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study..  68:296-305. 2008
  • Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis..  68:11-19. 2008
  • Sequence variation in alpha-methylacyl-CoA racemase and risk of early-onset and familial prostate cancer..  67:1507-1513. 2007
  • Genome-wide linkage of 77 families from the African American Hereditary Prostate Cancer study (AAHPC)..  67:22-31. 2007
  • Immunohistochemical characterization of neuroendocrine cells in prostate cancer.  66:1399-1406. 2006
  • Genome-wide linkage scan for prostate cancer aggressiveness loci using families from the University of Michigan Prostate Cancer Genetics Project..  66:173-179. 2006
  • INSPstI polymorphism and prostate cancer in African-American men..  65:83-87. 2005
  • Decreasing age at prostate cancer diagnosis over successive generations in prostate cancer families..  64:60-66. 2005
  • Lysophosphatidic acid promotes survival of androgen-insensitive prostate cancer PC3 cells via activation of NF-kappaB..  61:105-113. 2004
  • Genome-wide scan for prostate cancer susceptibility genes using families from the University of Michigan prostate cancer genetics project finds evidence for linkage on chromosome 17 near BRCA1..  57:326-334. 2003
  • Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system..  55:299-307. 2003
  • Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer..  55:71-80. 2003
  • R726L androgen receptor mutation is uncommon in prostate cancer families in the united states..  54:306-309. 2003
  • Selenomethionine does not affect PSA secretion independent of its effect on LNCaP cell growth..  54:315-321. 2003
  • Relationship of serum sex-steroid hormones and prostate volume in African American men..  53:322-329. 2002
  • Inhibition of human chorionic gonadotropin beta-subunit modulates the mitogenic effect of c-myc in human prostate cancer cells..  53:200-210. 2002
  • Insulin-like growth factor binding protein-3 induces early apoptosis in malignant prostate cancer cells and inhibits tumor formation in vivo..  51:141-152. 2002
  • Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin..  48:71-78. 2001
  • Reduced expression of hMSH2 and hMLH1 and risk of prostate cancer: a case-control study..  47:269-275. 2001
  • Rational basis for Trk inhibition therapy for prostate cancer..  45:140-148. 2000
  • Presence of receptors for bombesin/gastrin-releasing peptide and mRNA for three receptor subtypes in human prostate cancers..  42:295-303. 2000
  • Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group..  40:105-114. 1999
  • Double-blind, placebo-controlled trial to assess the efficacy and tolerability of mepartricin in the treatment of BPH..  37:246-252. 1998
  • Mutational analysis of the TrkA gene in prostate cancer..  36:172-180. 1998
  • Pharmacology of tamsulosin: saturation-binding isotherms and competition analysis using cloned alpha 1-adrenergic receptor subtypes..  33:55-59. 1997
  • Prostate-specific antigen-detected prostate cancer (stage T1c): an analysis of whole-mount prostatectomy specimens..  32:59-64. 1997
  • Mutations of the p16 gene product are rare in prostate cancer..  30:188-194. 1997
  • 6-Methylene progesterone is cytotoxic to human cancer cell lines independent of its 5-alpha-reductase activity..  26:28-34. 1995
  • A coaxial microwave applicator for transurethral hyperthermia of the prostate..  22:125-138. 1993
  • Infrequent RAS oncogene mutations in human prostate cancer..  20:327-338. 1992
  • Establishment of a long‐term adenocarcinoma of the prostate cell line in the nude mouse.  7:369-376. 1985
  • A serologic approach to the definition of human prostatic carcinoma antigens..  2:369-380. 1981
  • The clinical relevance of in vitro markers..  2:219-224. 1981